Mankind Pharma Launches Generic Version Of Empagliflozin Diabetes Medication
The launch follows the expiration of Boehringer Ingelheim's patent for Empagliflozin in India.
Mankind Pharma launched a generic version of Empagliflozin, a diabetes medication, in India under the brand names Empaglyde, Empagreat, and Dynaduo. The medication is available in various strengths, ranging from 10 mg to 25 mg.
The launch is expected to increase accessibility and affordability of the medication, with prices starting at Rs 5.49 for the 10 mg variant and Rs 9.90 for the 25 mg variant.
"With this launch, the drug has once again broken cost barriers by offering a product that combines international quality with affordability." Rajeev Juneja, Vice Chairman and Managing Director of Mankind Pharma said.
The launch follows the expiration of Boehringer Ingelheim's patent for Empagliflozin in India. Other companies, including Glenmark and Alkem Laboratories, have also launched generic versions of the medication.
"Our decision to deploy two separate teams to promote these offerings under distinct names ensures deeper market penetration and a broader reach in this highly competitive segment. Additionally, our extensive distribution network will ensure that this price innovation benefits patients in both urban and rural areas." Juneja said.
With Boehringer Ingelheim's blockbuster diabetes drug Empagliflozin getting off-patent in India, various drug firms have introduced its generic version.
(With Inputs From PTI)
